Meeting
2021 ASCO Annual Meeting
Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
Authors
Wei Wei
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
Wei Wei , Xiaohua Ban , Fan Yang , Yongwen Huang , Jibin Li , Ya Qiu , Xiaqin Cheng , Jundong Li , Min Zheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT04157491
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5583)
DOI
10.1200/JCO.2021.39.15_suppl.5583
Abstract #
5583
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.
First Author: Zhen Zeng
Poster
2022 ASCO Annual Meeting
Overall survival results from a phase II trial of anlotinib plus sintilimab in patients with recurrent advanced cervical cancer.
First Author: Qin Xu
Poster
2021 ASCO Annual Meeting
Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.
First Author: Qin Xu
Poster
2022 ASCO Annual Meeting
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
First Author: Huaying Wang